bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format
June 03 2020 - 4:05PM
Business Wire
bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to
the public health and safety concerns related to the novel
coronavirus (COVID-19) pandemic, to support the health and
well-being of its directors, employees and stockholders, the
location of the Company’s 2020 Annual Meeting of Stockholders
(including any adjournments or postponements, the “Annual Meeting”)
has been changed to a virtual format only.
As previously announced, the Annual Meeting will be held at 8:30
a.m., Eastern Time, on Thursday, June 18, 2020. Stockholders will
not be able to attend the Annual Meeting in person, but instead
will be able to attend virtually. You will be able to participate
in the annual meeting, vote your shares electronically and submit
your questions during the live audio webcast of the meeting by
visiting www.virtualshareholdermeeting.com/BLUE2020 and entering
your 16-digit control number found on the voting form that was
enclosed with the proxy materials for the Annual Meeting that were
previously distributed. If a stockholder encounters any
difficulties accessing the virtual meeting during the check-in or
meeting time, please call the technical support number
provided.
As described in the proxy materials for the Annual Meeting that
were previously distributed, stockholders are entitled to
participate in the Annual Meeting if they were a stockholder of the
Company as of the close of business on April 23, 2020, the record
date.
Whether or not a stockholder plans to participate in the live
webcast of the Annual Meeting, we urge all stockholders to vote and
submit their proxy in advance of the Annual Meeting by one of the
methods described in the proxy materials for the Annual Meeting
that were previously provided to the stockholders. The proxy card
included with the proxy materials previously distributed will not
be updated to reflect the change in location and may continue to be
used to vote stockholder shares in connection with the Annual
Meeting.
A notice regarding this change to a virtual meeting format is
being filed as additional proxy materials with the Securities and
Exchange Commission together with this press release.
About bluebird bio, Inc.
bluebird bio, Inc. (Nasdaq: BLUE) is pioneering gene therapy
with purpose. From our Cambridge, MA headquarters, we’re developing
gene therapies for severe genetic diseases and cancer, with the
goal that people facing potentially fatal conditions with limited
treatment options can live their lives fully. Beyond our labs,
we’re working to positively disrupt the healthcare system to create
access, transparency and education so that gene therapy can become
available to all those who can benefit.
bluebird bio is a human company powered by human stories. We’re
putting our care and expertise to work across a spectrum of
disorders including cerebral adrenoleukodystrophy, sickle cell
disease, ß-thalassemia and multiple myeloma, using three gene
therapy technologies: gene addition, cell therapy and
(megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, WA; Durham, NC;
and Zug, Switzerland.
bluebird bio is a trademark of bluebird bio, Inc.
Learn more at www.bluebirdbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200603005781/en/
Investors & Media Investors: Ingrid Goldberg,
410-960-5022 igoldberg@bluebirdbio.com OR Elizabeth Pingpank,
617-914-8736 epingpank@bluebirdbio.com
Media: Jenn Snyder, 617-448-0281 jsnyder@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024